Results 21 to 30 of about 14,237 (205)

Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells

Neoplasia: An International Journal for Oncology Research, 2022
BH3 mimetics are promising novel anticancer therapeutics. By selectively inhibiting BCL-2, BCL-xL, or MCL-1 (i.e. ABT-199, A-1331852, S63845) they shift the balance of pro- and anti-apoptotic proteins in favor of apoptosis.
Ufuk Erdogdu, Nadezda Dolgikh, Stephanie Laszig, Vinzenz Särchen, Michael T. Meister, Marek Wanior, Stefan Knapp, Cathinka Boedicker   +7 more
doaj   +1 more source

Impact of Short-Term (+)-JQ1 Exposure on Mouse Aorta: Unanticipated Inhibition of Smooth Muscle Contractility

Cells, 2023
(+)-JQ1, a specific chemical inhibitor of bromodomain and extraterminal (BET) family protein 4 (BRD4), has been reported to inhibit smooth muscle cell (SMC) proliferation and mouse neointima formation via BRD4 regulation and modulate endothelial nitric ...
Binjie Yan, Yu Gui, Yanan Guo, Jiaxing Sun, Mahmoud Saifeddine, Jingti Deng, Joseph A. Hill, Morley D. Hollenberg, Zhi-Sheng Jiang, Xi-Long Zheng   +9 more
doaj   +1 more source

BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction [PDF]

Journal of Dental Research, 2014
BET proteins are a group of epigenetic regulators controlling transcription through reading acetylated histone tails and recruiting transcription complexes. They are considered as potential therapeutic targets in many distinct diseases. A novel synthetic bromodomain and extraterminal domain (BET) inhibitor, JQ1, was proved to suppress oncogene ...
S, Meng, L, Zhang, Y, Tang, Q, Tu, L, Zheng, L, Yu, D, Murray, J, Cheng, S H, Kim, X, Zhou, J, Chen   +10 more
openaire   +2 more sources

The BET inhibitor attenuates the inflammatory response and cell migration in human microglial HMC3 cell line

Scientific Reports, 2021
Microglia, resident macrophages of the brain that act as primary immune cells, play essential roles in innate immunity and neuroinflammatory pathologies.
Mina Baek, Eunyoung Yoo, Hae In Choi, Ga Yeong An, Jin Choul Chai, Young Seek Lee, Kyoung Hwa Jung, Young Gyu Chai   +7 more
doaj   +1 more source

Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation

Cell Reports, 2020
Summary: JQ1 is a BET-bromodomain inhibitor that has immunomodulatory effects. However, the precise molecular mechanism that JQ1 targets to elicit changes in antibody production is not understood. Our results show that JQ1 induces apoptosis, reduces cell
Isabella Y. Kong, Joel S. Rimes, Amanda Light, Izabela Todorovski, Sarah Jones, Eric Morand, Deborah A. Knight, Ylva E. Bergman, Simon J. Hogg, Hendrik Falk, Brendon J. Monahan, Paul A. Stupple, Ian P. Street, Susanne Heinzel, Philippe Bouillet, Ricky W. Johnstone, Philip D. Hodgkin, Stephin J. Vervoort, Edwin D. Hawkins   +18 more
doaj   +1 more source

Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4

Oncogenesis, 2021
Targeting the epigenome to modulate gene expression programs driving cancer development has emerged as an exciting avenue for therapeutic intervention.
Jack Calder, Amy Nagelberg, Jennifer Luu, Daniel Lu, William W. Lockwood   +4 more
doaj   +1 more source

The top 10 common genes upregulated or downregulated from 009P1-, 009P2-, (+)-JQ1- and SAHA-treated BCBL-1 cells.

, 2023
The top 10 common genes upregulated or downregulated from 009P1-, 009P2-, (+)-JQ1- and SAHA-treated BCBL-1 cells.
Tran Phuc (3948350), Zhen Lin (172016), Lu Dai (528895), Zhengzhu Chen (14425314), Zhengyu Wang (8437125), Zhigang Xu (378834), Zhiqiang Qin (66680), Jungang Chen (367400), Donglin Yang (490406), Hong-yu Li (1321812), Samantha Kendrick (1311831)   +10 more
core   +1 more source

General mechanism of JQ1 in inhibiting various types of cancer

Molecular Medicine Reports, 2020
Bromodomain‑containing 4 (BRD4) is a histone modification reader and transcriptional regulator that has been reported to interact with acetylated lysine histone motifs transcription factors (TFs), transcription co‑activators and RNA polymerase II. The selective small molecule inhibitor JQ1, which binds competitively to bromodomains, has been reported ...
Jiang, Guojuan, Deng, Wanglong, Liu, Yang, Wang, Chengde   +3 more
openaire   +3 more sources

JQ1 is a potential therapeutic option for COPD patients with agrin overexpression [PDF]

American Journal of Physiology-Lung Cellular and Molecular Physiology, 2018
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and death worldwide. It is characterized by chronic pulmonary inflammation and obstructed airflow from the lungs. To date, there is no effective treatment for COPD. The activation of the agrin (AGRN-YAP pathway can promote heart regeneration. Because agrin can induce
Zhen, Xiao, Jing, Shu, Feng, Zhou, Yong, Han   +3 more
openaire   +2 more sources

A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-κB pathways

Cell Death and Disease, 2021
Bromodomain-containing protein 4 (BRD4) has emerged as a promising treatment target for bone-related disorders. (+)-JQ1, a thienotriazolodiazepine compound, has been shown to inhibit pro-osteoclastic activity in a BRD4-dependent approach and impede bone ...
Ying Liu, Wenjie Liu, Ziqiang Yu, Yan Zhang, Yinghua Li, Dantao Xie, Gang Xie, Li Fan, Shipeng He   +8 more
doaj   +1 more source